Financial toxicity in patients with leukemia undergoing hematopoietic stem cell transplantation: A systematic review

IF 2.2 4区医学 Q3 HEMATOLOGY

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI:10.1016/j.beha.2023.101469

Orrin Pail , Thomas G. Knight

{"title":"Financial toxicity in patients with leukemia undergoing hematopoietic stem cell transplantation: A systematic review","authors":"Orrin Pail , Thomas G. Knight","doi":"10.1016/j.beha.2023.101469","DOIUrl":null,"url":null,"abstract":"<div>Financial toxicity (FT) is a term used to describe the objective financial burden of cancer care including the associated coping behaviors used by patients and their caregivers. FT has been shown to result in both direct financial burdens and in clinically relevant outcomes, such as non-adherence with care, diminished quality of life, and even decreased overall survival. Much of the data has been described in solid tumors, with limited investigations in the malignant hematology population. Patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT) face a unique financial burden driven by lengthy hospitalizations and acute and chronic morbidity that have downstream implications on their income and costs. In this review, we discuss the prevalence of FT in patients with leukemia who are eligible for HSCT. We review the impact of FT on financial and clinical outcomes and the role of various interventions that have been studied within this population.</div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research Clinical Haematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521692623000300","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Financial toxicity (FT) is a term used to describe the objective financial burden of cancer care including the associated coping behaviors used by patients and their caregivers. FT has been shown to result in both direct financial burdens and in clinically relevant outcomes, such as non-adherence with care, diminished quality of life, and even decreased overall survival. Much of the data has been described in solid tumors, with limited investigations in the malignant hematology population. Patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT) face a unique financial burden driven by lengthy hospitalizations and acute and chronic morbidity that have downstream implications on their income and costs. In this review, we discuss the prevalence of FT in patients with leukemia who are eligible for HSCT. We review the impact of FT on financial and clinical outcomes and the role of various interventions that have been studied within this population.

查看原文本刊更多论文

接受造血干细胞移植的白血病患者的财务毒性:一项系统综述

经济毒性（FT）是一个术语，用于描述癌症护理的客观经济负担，包括患者及其护理人员使用的相关应对行为。FT已被证明会导致直接的经济负担和临床相关结果，如不遵守护理、生活质量下降，甚至降低总生存率。大部分数据都是在实体瘤中描述的，对恶性血液学人群的研究有限。接受造血干细胞移植（HSCT）的血液系统恶性肿瘤患者面临着独特的经济负担，这是由于长期住院和急慢性发病率对他们的收入和成本产生了下游影响。在这篇综述中，我们讨论了符合HSCT条件的白血病患者中FT的患病率。我们回顾了FT对财务和临床结果的影响，以及在该人群中研究的各种干预措施的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Best Practice & Research Clinical Haematology 医学-血液学

CiteScore

4.20

自引率

0.00%

发文量

审稿时长

35 days

期刊介绍： Best Practice & Research Clinical Haematology publishes review articles integrating the results from the latest original research articles into practical, evidence-based review articles. These articles seek to address the key clinical issues of diagnosis, treatment and patient management. Each issue follows a problem-orientated approach which focuses on the key questions to be addressed, clearly defining what is known and not known, covering the spectrum of clinical and laboratory haematological practice and research. Although most reviews are invited, the Editor welcomes suggestions from potential authors.